Drug-Related Adverse Events of Osteoporosis Therapy
Drug-Related Adverse Events of Osteoporosis Therapy
复制标题
DOI：
10.1016/j.ecl.2016.09.009
复制
发表时间：
2017-03-01
影响因子：
4.5
通讯作者：
Khan, Aliya A.
中科院分区：
文献类型：
--
作者：
Khan, Moira;Cheung, Angela M.;Khan, Aliya A.
Postmenopausal osteoporosis is associated with microarchitectural deterioration and increased risk of fracture. Osteoporosis therapy effectively reduces the risk of vertebral, nonvertebral, and hip fracture and been associated with increased survival. Currently approved treatments for osteoporosis include bisphosphonates, denosumab, selective estrogen receptor modulators, and teriparatide. This article reviews the adverse events of therapy associated with these medical interventions. Hormone replacement therapy is not included, because it is no longer indicated for the treatment of osteoporosis in all countries. Calcitonin and strontium ranelate are also not included, because their indication for osteoporosis has recently been limited or withdrawn.
